Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415461 | 0.93 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL493726 | 0.93 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL493745 | 0.91 | TACR2 (0.43) | TACR2TACR1 | |
| SCHEMBL3766385 | 0.89 | TACR2 (0.44) | TACR2TACR1 | |
| Fumaric Acid SCHEMBL493497 | 0.89 | TACR2 (0.43) | TACR2TACR1 | |
| Maleic Acid SCHEMBL493496 | 0.89 | TACR2 (0.43) | TACR2TACR1 | |
| SCHEMBL493759 | 0.89 | TACR2 (0.49) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL3766672 | 0.88 | TACR2 (0.43) | TACR2TACR1 | |
| SCHEMBL5028804 | 0.88 | TACR2 (0.45) | TACR2TACR1 | |
| SCHEMBL3764734 | 0.88 | TACR2 (0.45) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | claimed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | claimed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | TACR2 110/4885TACR1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.